Equillium appoints Dr. Barbara Troupin, former Myokardia SVP, to Board

Equillium, Inc.

Appointed Dr. Barbara Troupin, M.D., as a class I director, effective February 24, 2022.
Will serve on the Nominating and Corporate Governance Committee.
Dr. Troupin was most recently SVP at Myokardia; prior CMO at ERX Pharmaceuticals, Aquinox, Apricus Biosciences.
Chairman cited her experience as Equillium prepares to initiate Phase 3 study in aGVHD and expand programs with Bioniz assets.

item 5.02 item 8.01 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Barbara Troupin

Director

EQ · Equillium, Inc.

Effective: 2022-02-24
Filed: March 2, 2022, 6:59 PM ET

Effective February 24, 2022, the Board increased the number of directors to nine and appointed Dr. Barbara Troupin, M.D., as a class I director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Barbara Troupin was appointed as Director at Equillium, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective February 24, 2022, the Board increased the number of directors to nine and appointed Dr. Barbara Troupin, M.D., as a class I director of the Company, effective immediately.

View on SEC.gov

Equillium, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-002622

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.